Great Point Partners LLC purchased a new position in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 514,659 shares of the company's stock, valued at approximately $12,614,000. Oruka Therapeutics comprises about 3.7% of Great Point Partners LLC's portfolio, making the stock its 11th biggest position. Great Point Partners LLC owned about 42.53% of Oruka Therapeutics at the end of the most recent quarter.
Separately, The Manufacturers Life Insurance Company purchased a new position in Oruka Therapeutics in the third quarter valued at approximately $1,037,000. Institutional investors own 56.44% of the company's stock.
Analyst Upgrades and Downgrades
ORKA has been the subject of several research reports. Lifesci Capital began coverage on shares of Oruka Therapeutics in a research note on Monday, September 16th. They set an "outperform" rating and a $41.00 price objective for the company. Leerink Partners started coverage on shares of Oruka Therapeutics in a research report on Tuesday, September 17th. They set an "outperform" rating and a $44.00 price target for the company. TD Cowen started coverage on Oruka Therapeutics in a research report on Monday, September 16th. They issued a "buy" rating on the stock. Stifel Nicolaus assumed coverage on Oruka Therapeutics in a research note on Friday, October 11th. They set a "buy" rating and a $49.00 price objective on the stock. Finally, HC Wainwright reaffirmed a "buy" rating and set a $45.00 target price on shares of Oruka Therapeutics in a report on Monday. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Oruka Therapeutics presently has a consensus rating of "Buy" and an average target price of $43.17.
Read Our Latest Analysis on Oruka Therapeutics
Oruka Therapeutics Stock Up 8.4 %
ORKA traded up $1.57 during trading hours on Wednesday, hitting $20.26. The company's stock had a trading volume of 51,265 shares, compared to its average volume of 67,913. Oruka Therapeutics, Inc. has a fifty-two week low of $18.20 and a fifty-two week high of $53.88. The business's 50-day moving average is $25.76. The stock has a market capitalization of $709.08 million, a price-to-earnings ratio of -3.24 and a beta of 0.87.
Oruka Therapeutics Company Profile
(
Free Report)
ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company's cardiovascular science, ARCA's management team has significant experience in developing and commercializing cardiovascular products.
Featured Stories
Before you consider Oruka Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oruka Therapeutics wasn't on the list.
While Oruka Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
